

PD-L1 Analysis

Ordered By: PaigelA Diagnosis: NSCLC

Patient ID: AP829279D Histologic Subtype: Adenocarcinoma

Date Received: 28Feb2022 Stain: DAKO 22-C3

Scanner Description: Aperio

Results

Tumor Proportion Score (TPS): 3.295%

Interpretation: Positive

Table 1: Scoring Interpretation for 22C3 PD-L1 staining in NSCLC

| Expression Leve | I TPS | Staining Pattern |
|-----------------|-------|---|
| Negative | <1 | Partial or complete cell membrane staining in <1% of viable tumor cells |
| Positive | ≥1 | Partial or complete cell membrane staining in 1-49% of viable tumor cells |
| High Positive | ≥50 | Partial or complete cell membrane staining in ≥50% of viable tumor cells |

Abbreviations: TPS; Tumor Proportion Score, NSCLC; Non-small cell lung cancer

Supportive TME Analysis

Research Use Only
Not For Use in Diagnostic Procedures

TME PD-L1 Response

| Moderate | | TC or IC PD-L1 Expression | DD 11 Evergosian (Vac | and Na) | | |
|-------------|-------------------------|---------------------------|------------------------------|------------|-------------------------------|---------------------|
| TC= 3.295% | <u>Category</u> High | >50% | PD-L1 Expression (Yes | 6% | TC or IC High | <u>eveis</u> 16% |
| IC= 10.296% | Moderate | >5% - 50% | IC Only | 33% | TC or IC Moderate | 21% |
| | Low None | 1% - 5% <1% | TC and IC Neither TC nor IC | 26% 35% | TC or IC Low TC or IC None | 26% 35% |

Immune Cell Fraction

| V | ery | Low |
|---|-----|-----|
| | | |

Mac + Lymph= 0.131 %

| <u>Category</u> | Mac + Lym Cell Fraction_ | Macrophage and Lym | phocyte Cell Fraction |
|-----------------|--------------------------|--------------------|-----------------------|
| High | >20% | High | 10% |
| Moderate | >5% - <20% | Moderate | 50% |
| Low | 1% - <5% | Low | 30% |
| Very Low | <1% | Very Low | 10% |





Supportive TMA Analysis

Research Use Only Not For Use in Diagnostic Procedures

Lymphocyte Analysis

| Compartment | % Positive | % Cellularity | H-Score |
|---------------------|------------|---------------|---------|
| All Lymphocytes | 16.97% | 0.0597% | 51 |
| Tumor Lymphocytes | 10.265% | 0.0106% | 31 |
| Stromal Lymphocytes | 17.867% | 0.107% | 54 |
| Margin Lymphocytes | 17.823% | 0.0597% | 53 |

Macrophage Analysis

| Compartment | % Positive | % Cellularity | H-Score |
|---------------------|------------|---------------|---------|
| All Macrophages | 6.729% | 0.0852% | 20 |
| Tumor Macrophages | 9.061% | 0.0321% | 27 |
| Stromal Macrophages | 6.099% | 0.161% | 18 |
| Margin Macrophages | 7.299% | 0.1% | 22 |

PD-L1 H-Score Intensity

| Compartment | H Score |
|--------------|---------|
| Whole Tissue | 14 |
| Tumor | 10 |
| Stroma | 20 |
| Margin | 16 |

| PD-L1 Density | | |
|---------------|--------------------------|--|
| Compartment | Positive/mm ² | |
| Whole Tissue | 260 | |
| Tumor | 228 | |
| Stroma | 308 | |
| Margin | 195 | |
| IC | 718 | |

PD-L1 Scoring Paradigms

| Endpoint | Score | |
|-------------|---------|--|
| TPS | 3.295% | |
| IC Present | 13199 | |
| IC Positive | 10.296% | |

| Name and Title | Signature and Date |
|---|--------------------|
| Roberto Gianani, MD Medical Director | |

Flagship Biosciences CAP#: 8860624

Customer Support:

tissueinsight-notifications@flagshipbio.com

720.902.4787